
    
      This is a multicentre, prospective, study of EGFR mutation status in advanced NSCLC patients
      (locally advanced and/or metastatic disease) with adenocarcinoma histology proposed to be
      conducted at 15 sites from different geographical regions across India. The study targets to
      enrol 268 patients over a period of 6 months. The study will enroll patients with
      histologically confirmed, systemic treatment na√Øve adenocarcinoma metastatic cancer (stage
      IV). This will be a single visit study. No study medication will be prescribed or
      administered as a part of study procedure.
    
  